ALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity

MT Newswires Live

Apr 26

ALX Oncology (ALXO) said Friday that data from its ongoing phase 1/2 trial of its evorpacept investigational drug in combination with rituximab and lenalidomide in patients with indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma showed anti-tumor activity.

A median follow-up of 28 months on the patients revealed that the two-year progression-free survival rate was 69% and the two-year overall survival rate was 84%, while 80% achieved complete responses, the company said.

The complete response rate was higher than that of patients who received the standard-of-care rituximab and lenalidomide treatment, the company said.

The phase 2 portion of the study in patients with previously untreated indolent non-Hodgkin lymphoma is ongoing and has completed enrollment, the company added.

Shares of the company were down 9.3% in recent Friday trading.

Price: 0.55, Change: -0.06, Percent Change: -9.32

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2530163491"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530163491\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2530163491?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-26 01:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530163491","market":"fut","top_or_hot":-1,"title":"ALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity","media":"MT Newswires Live","content":"<html><body><p> ALX Oncology (ALXO) said Friday that data from its ongoing phase 1/2 trial of its evorpacept investigational drug in combination with rituximab and lenalidomide in patients with indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma showed anti-tumor activity.</p><p>A median follow-up of 28 months on the patients revealed that the two-year progression-free survival rate was 69% and the two-year overall survival rate was 84%, while 80% achieved complete responses, the company said.</p><p>The complete response rate was higher than that of patients who received the standard-of-care rituximab and lenalidomide treatment, the company said.</p><p>The phase 2 portion of the study in patients with previously untreated indolent non-Hodgkin lymphoma is ongoing and has completed enrollment, the company added.</p><p>Shares of the company were down 9.3% in recent Friday trading.</p><p>Price: 0.55, Change: -0.06, Percent Change: -9.32</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-26 01:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> ALX Oncology (ALXO) said Friday that data from its ongoing phase 1/2 trial of its evorpacept investigational drug in combination with rituximab and lenalidomide in patients with indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma showed anti-tumor activity.</p><p>A median follow-up of 28 months on the patients revealed that the two-year progression-free survival rate was 69% and the two-year overall survival rate was 84%, while 80% achieved complete responses, the company said.</p><p>The complete response rate was higher than that of patients who received the standard-of-care rituximab and lenalidomide treatment, the company said.</p><p>The phase 2 portion of the study in patients with previously untreated indolent non-Hodgkin lymphoma is ongoing and has completed enrollment, the company added.</p><p>Shares of the company were down 9.3% in recent Friday trading.</p><p>Price: 0.55, Change: -0.06, Percent Change: -9.32</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALXO","symbol_name":"ALX Oncology Holdings","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2530163491","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530163491","pubTimestamp":1745603098,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ALX Oncology  said Friday that data from its ongoing phase 1/2 trial of its evorpacept investigational drug in combination with rituximab and lenalidomide in patients with indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma showed anti-tumor activity.A median follow-up of 28 months on the patients revealed that the two-year progression-free survival rate was 69% and the two-year overall survival rate was 84%, while 80% achieved complete responses, the company said.The complete response rate was higher than that of patients who received the standard-of-care rituximab and lenalidomide treatment, the company said.The phase 2 portion of the study in patients with previously untreated indolent non-Hodgkin lymphoma is ongoing and has completed enrollment, the company added.Shares of the company were down 9.3% in recent Friday trading.Price: 0.55, Change: -0.06, Percent Change: -9.32","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALXO":"ALX Oncology Holdings","BK4231":"零售房地产信托","ALX":"亚历山大公司","BK4080":"零售业房地产投资信托","BK4139":"生物科技"},"translate_title":"ALX Oncology 1/2期Evorpacept治疗B细胞非霍奇金淋巴瘤试验显示抗肿瘤活性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALX":1,"ALXO":0.9},"content_text":"ALX Oncology (ALXO) said Friday that data from its ongoing phase 1/2 trial of its evorpacept investigational drug in combination with rituximab and lenalidomide in patients with indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma showed anti-tumor activity.A median follow-up of 28 months on the patients revealed that the two-year progression-free survival rate was 69% and the two-year overall survival rate was 84%, while 80% achieved complete responses, the company said.The complete response rate was higher than that of patients who received the standard-of-care rituximab and lenalidomide treatment, the company said.The phase 2 portion of the study in patients with previously untreated indolent non-Hodgkin lymphoma is ongoing and has completed enrollment, the company added.Shares of the company were down 9.3% in recent Friday trading.Price: 0.55, Change: -0.06, Percent Change: -9.32","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}